LAKE FOREST, Ill., May 13, 2015 /PRNewswire/ -- Hospira, Inc.
(NYSE: HSP), the world's leading provider of injectable drugs and
infusion technologies, and a global leader in biosimilars,
announced that Hospira shareholders voted in favor of the proposal
to adopt the merger agreement with Pfizer Inc. at a special meeting
of stockholders held today, May 13,
2015, in Denver, Colo.
On Feb. 5, 2015, Hospira and
Pfizer Inc. announced they had entered into a merger agreement
under which Pfizer will acquire Hospira for $90 per share in
cash for a total enterprise value of approximately $17 billion. The merger is subject to customary
closing conditions, one of which was approval of the merger by
Hospira's shareholders. Additional closing conditions to be met
include obtaining regulatory approvals in several
jurisdictions.
At the Special Meeting today, 140.8 million shares were voted in
favor of the merger agreement, or 99.4 percent of shares voted
for the merger proposal and approximately 81.5 percent of
Hospira's outstanding shares.
Hospira and Pfizer continue to expect the merger to close in the
second half of 2015.
A full description of the proposed merger is included in the
proxy statement for the special meeting, available at
www.hospirainvestor.com.
About Hospira
Hospira, Inc. is the world's leading provider of injectable
drugs and infusion technologies, and a global leader in
biosimilars. Through its broad, integrated portfolio, Hospira is
uniquely positioned to Advance Wellness™ by improving patient and
caregiver safety while reducing healthcare costs. The company is
headquartered in Lake Forest, Ill.
Learn more at www.hospira.com.
Private Securities Litigation Reform Act of
1995 --
A Caution Concerning Forward-Looking
Statements
Information provided and statements contained in this release
that are not purely historical are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as
amended, and the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements only speak as of the date of this
report and the company assumes no obligation to update the
information included in this report. Such forward-looking
statements include statements regarding the proposed merger with
Pfizer Inc. These statements often include words such as "will,"
believe," "expect," "anticipate," "intend," "plan," "estimate," or
similar expressions. These statements are not guarantees of
performance or results and they involve risks, uncertainties, and
assumptions. For a further description of these factors, see the
risk factors set forth in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K for
the fiscal year ended December 31,
2014 and subsequent Form 10-Q. Additional factors may
include the effect of the announcement of the merger and related
transactions on Hospira's business relationships, operating results
and business generally; the occurrence of any event, change or
other circumstances that could give rise to the termination of the
merger agreement with Pfizer Inc., and the risk that the merger
agreement with Pfizer Inc. may be terminated in circumstances that
require Hospira to pay a termination fee to Pfizer Inc.; the
outcome of any legal proceedings that have been, or may be,
instituted against Hospira related to the merger agreement with
Pfizer Inc.; and the failure to satisfy conditions to completion of
the merger with Pfizer Inc., including the receipt of all required
regulatory approvals related to the merger with Pfizer Inc.
Although we believe that these forward-looking statements are based
on reasonable assumptions, there are many factors that could affect
our actual financial results or results of operations and could
cause actual results to differ materially from those in the
forward-looking statements. All future written and oral
forward-looking statements by us or persons acting on our behalf
are expressly qualified in their entirety by the cautionary
statements contained or referred to above. Except for our ongoing
obligations to disclose material information as required by the
federal securities laws, we do not have any obligations or
intention to release publicly any revisions to any forward-looking
statements to reflect events or circumstances in the future or to
reflect the occurrence of unanticipated events.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/hospira-shareholders-approve-merger-of-hospira-and-pfizer-at-special-meeting-300082777.html
SOURCE Hospira, Inc.